In a safety measure executed earlier this year, the FDA and Bristol-Myers Squibb agreed to add a warning to the label of Tequin, an antibiotic used primarily in the treatment of chronic bronchitis and other ailments, stating that it should not be used by those suffering from diabetic complications. A Canadian study released in March of 2006 found Tequin users four times more likely to become hospitalized due to low blood sugar complications and 17 times more likely to develop serious diabetes than users of other antibiotics. Bristol-Myers Squibb announced May 1st that it will no longer make and sell the dangerous product.
Between January 1, 2000, and June 30, 2005, the consumer group Public Citizen recorded 388 people who experienced dangerous blood abnormalities under the use of Tequin. Of these patients, 159 became hospitalized and 20 died. Although the manufacturer is halting all production of the product, they will not pull those examples currently existing on store shelves.
If you or someone you know has experienced difficulties from the drug Tequin, please contact a personal injury lawyer such as Jacoby and Meyers in Los Angeles, California for a consultation.
